Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals by Quarter
Crinetics Pharmaceuticals — Stock-based compensation expense ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals: $24.9M in Q2 2026, down 4.7% from a year earlier.
Latest, Q2 2026
24.9
Period ended Jun 30, 2026
Change on a year earlier
-4.7%
26.1 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
29
Documents cited below
Where the Q2 2026 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Stock-based compensation expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 24.9 | -4.7% | SEC Filing ↗ |
| Q1 2026 | Mar 31, 2026 | 29.7 | +44.9% | SEC Filing ↗ |
| Q4 2025 | Dec 31, 2025 | 21.7 | +15.2% | SEC Filing ↗ |
| Q3 2025 | Sep 30, 2025 | 22.7 | +25.1% | SEC Filing ↗ |
| Q2 2025 | Jun 30, 2025 | 26.1 | +37.9% | SEC Filing ↗ |
| Q1 2025 | Mar 31, 2025 | 20.5 | +52.3% | SEC Filing ↗ |
| Q4 2024 | Dec 31, 2024 | 18.9 | +62.2% | SEC Filing ↗ |
| Q3 2024 | Sep 30, 2024 | 18.2 | +64.3% | SEC Filing ↗ |
| Q2 2024 | Jun 30, 2024 | 18.9 | +86.2% | SEC Filing ↗ |
| Q1 2024 | Mar 31, 2024 | 13.5 | +66.0% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 11.6 | +46.0% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 11.1 | +48.7% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 10.2 | +42.6% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 8.10 | +40.9% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 7.96 | +54.3% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 7.43 | +63.3% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 7.13 | +68.6% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 5.75 | +68.6% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 5.16 | +73.7% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 4.55 | +63.7% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 4.23 | +67.2% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 3.41 | +58.6% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 2.97 | +62.3% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 2.78 | +50.3% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 2.53 | +60.1% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 2.15 | +108.7% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 1.83 | +115.3% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 1.85 | +140.3% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 1.58 | +485.2% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 1.03 | +139.5% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 0.85 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 0.77 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | 0.27 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | 0.43 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-sbc-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.